Company intelligence / Profile preview

Xenios

Heilbronn, Baden-Württemberg, Germanyxeniosusa.com ↗

Ownership: Private
Development stage: Commercial

Overview

Xenios’s core products—including the Novalung system—are approved in major markets such as the US, Europe, and China for ECMO therapy. The company has received FDA clearance in the US for long-term ECMO use (>6 hours) and MDR approval in Europe for its latest generation device. Clinical results have established these systems as vital tools in intensive care medicine to improve survival rates among patients with severe cardiac or pulmonary failure.

Therapeutic areas: PulmonologyCardiovascular
Modalities: DeviceBiologic
Industry: Therapeutic Medical Devices

Partnerships

XOR Labs Canada Inc.academic collaborations not specified but likely due to clinical research focus.

Beyond the preview

Go deeper on Xenios.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xenios.

Explore the full profile